pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuri
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
Phase 1 · other · Incomplete Response - Major Depressive Disorder (IR-MDD)
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults for Incomplete Response - Major Depressive Disorder (IR-MDD) is a Phase 1 program (other) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).
Internal code 358-201-00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Otsuka Beijing Research Institute
- Phase
- Phase 1
- Modality
- other
- Indication
- Incomplete Response - Major Depressive Disorder (IR-MDD)
- Status
- active
- Trials
- 1